Biopharmaceutical group Ablynx has made some changes to its board of directors after recently declining a takeover proposal for the second time from Novo Nordisk.
Heading up the board is Ablynx’s non-executive director Dr Bo Jesper Hensen (pictured), who was unanimously elected as its new chairman.
He succeeds Dr Peter Fellner – who has served as chairman since 2013 but resigned with immediate effect shortly after the company turned down Novo’s unsolicited offer.
Dr Hensen’s expertise lies in orphan drug research and development, international marketing and commercialisation and has experience in regulatory, pharmacovigilance, medical marketing and business development knowledge.
Dr Edwin Moses, chief executive officer at Ablynx, said: “We are very fortunate to have an extremely suitable successor with Bo Jesper, allowing for an orderly transition at this important time.
“Hensen is the ideal person to lead the board moving forward and his wealth of experience is particularly relevant as we advance towards the potential approvals and global launches of our lead, wholly-owned product, caplacizumab, in addition to advancing our extensive pipeline.”
Source: PM Live
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.